PGEN
NASDAQ · Biotechnology
Precigen Inc
$3.19
+0.06 (+1.92%)
Financial Highlights (FY 2026)
Revenue
5.26M
Net Income
-168,862,736
Gross Margin
-8.7%
Profit Margin
-3,216.2%
Rev Growth
-35.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -8.7% | -8.7% | 42.3% | 42.3% |
| Operating Margin | -3,440.2% | -3,096.2% | -7.4% | -9.4% |
| Profit Margin | -3,216.2% | -3,055.4% | -8.5% | -8.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 5.26M | 8.10M | 411.38M | 421.12M |
| Gross Profit | -458,550 | -705,570 | 173.84M | 177.96M |
| Operating Income | -181,116,034 | -250,814,633 | -30,534,477 | -39,472,830 |
| Net Income | -168,862,736 | -233,845,918 | -34,816,902 | -35,997,358 |
| Gross Margin | -8.7% | -8.7% | 42.3% | 42.3% |
| Operating Margin | -3,440.2% | -3,096.2% | -7.4% | -9.4% |
| Profit Margin | -3,216.2% | -3,055.4% | -8.5% | -8.6% |
| Rev Growth | -35.0% | -35.0% | +17.8% | -9.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 657.59M | 697.63M |
| Total Equity | — | — | 694.85M | 748.63M |
| D/E Ratio | — | — | 0.95 | 0.93 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -167,107,853 | -244,272,134 | -49,679,638 | -48,292,540 |
| Free Cash Flow | — | — | -21,385,787 | -28,685,035 |